Background: In 2007, in Indonesia 80% of a total 495 districts/municipalities was malaria endemic. Most malaria parasitemia is P. falciparum, and it is related to several risk factors. This analysis aimed to identify dominant risk factors related to P. falciparummalaria parasitemia among children 10 years or below. Methods: This analysis used a part of Basic Health Research year 2010 data. A…
In monitoring the treatment of malaria with Dihydroartemisinin-piperaquine (DHP), microscopic cross check and Polymerase Chain Reaction (PCR) performed to validate the results of laboratory examinations in the field. This study used finger prick samples from subjects with a diagnosis of malaria in monitoring the treatment of malaria with DHP in Kalimantan and Sulawesi. Samples taken at day 0, b…
Background. Since 2004, Malaria Program in Indonesia has used Artemisinin Combination Therapy (ACT) to replace the chloroquine resistance. The recommended ACT is Artesunate dan Amodiaquine (AAQ) combination for uncomplicated falciparum malaria. To relieve side effects and clinical complaints of malaria , health workers usually gave symptomatic and other drugs in addition to antimalarial drugs.…
Since 2008, Dihydroartemisinin-Piperaquine (DHP) has been used as the first-line drug for treatment of falciparum malaria in Papua, which gradually will also be used in other endemic areas. The objective of the study was to determine the safety and efficacy of DHP. Patients with uncomplicated malaria due to Plasmodium falciparum were enrolled and treated with supervised DHP (arterakin ®, no. …